4,918 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Purchased by Nebula Research & Development LLC

Nebula Research & Development LLC acquired a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 4,918 shares of the company's stock, valued at approximately $378,000.

Several other institutional investors also recently modified their holdings of WGS. William Blair Investment Management LLC acquired a new position in shares of GeneDx in the 4th quarter valued at about $51,496,000. Lord Abbett & CO. LLC acquired a new position in GeneDx in the fourth quarter valued at approximately $48,458,000. Science & Technology Partners L.P. bought a new position in shares of GeneDx during the 4th quarter worth approximately $30,821,000. Zweig DiMenna Associates LLC acquired a new stake in shares of GeneDx during the 4th quarter worth approximately $23,788,000. Finally, Raymond James Financial Inc. acquired a new position in shares of GeneDx during the 4th quarter valued at $20,371,000. Institutional investors own 61.72% of the company's stock.

Insiders Place Their Bets

In other news, CFO Kevin Feeley sold 922 shares of GeneDx stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $94.72, for a total value of $87,331.84. Following the transaction, the chief financial officer now owns 5,446 shares in the company, valued at approximately $515,845.12. The trade was a 14.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Katherine Stueland sold 2,154 shares of the firm's stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $113.09, for a total transaction of $243,595.86. Following the completion of the transaction, the chief executive officer now owns 3,440 shares in the company, valued at $389,029.60. This represents a 38.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 139,390 shares of company stock worth $13,043,288 in the last three months. 27.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on WGS shares. Wells Fargo & Company decreased their price target on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating for the company in a research note on Thursday, May 1st. TD Cowen upped their price target on GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research note on Tuesday, January 7th. The Goldman Sachs Group raised their price objective on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. Finally, TD Securities lowered their target price on GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, GeneDx has an average rating of "Moderate Buy" and a consensus target price of $78.14.

GeneDx Stock Performance

Shares of NASDAQ WGS traded down $4.94 during midday trading on Tuesday, reaching $61.22. The company's stock had a trading volume of 321,802 shares, compared to its average volume of 719,806. The firm has a 50 day moving average price of $93.64 and a 200-day moving average price of $82.95. The stock has a market capitalization of $1.72 billion, a P/E ratio of -31.23 and a beta of 1.96. GeneDx Holdings Corp. has a 12-month low of $18.80 and a 12-month high of $117.75. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGS - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.17. The firm had revenue of $87.12 million for the quarter, compared to analysts' expectations of $79.90 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, equities analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.